CAR-T Companies Proliferate: List of 100+ CAR-T Companies Worldwide

Chimeric antigen receptor T-cell therapy (CAR-T) is an approach that is being explored as an alternative to conventional treatments for several forms of cancer. Learn more about innovative CAR-T cell therapy companies and the technologies they use to fight cancer. This article features 100+ of the leading CAR-T cell therapy companies worldwide.

6th Perinatal Stem Cell Society Congress, March 5-6, 2020 (Salt Lake City, UT)

Hosted by the Perinatal Stem Cell Society, this two-day event will feature the world’s leading perinatal stem cell researchers, specializing in Amnion, Amniotic Fluid, Cord Blood for Regenerative Medicine, Cord Tissue, and the Placenta. Its scientific program will cover all aspects of the perinatal stem cell field, with opportunities to learn from leading clinicians utilizing cellular therapies within their practices. Click here to learn more or register.

Adaptimmune Receives RMAT Designation for ADP-A2M4 for Synovial Sarcoma Adaptimmune

Adaptimmune Therapeutics (Nasdaq:ADAP) has been granted a Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. FDA for ADP-A2M4 in the treatment of Synovial Sarcoma. Previously, the FDA had awarded an Orphan Drug Designation (ODD) to ADP-A2M4 for the treatment of soft tissue sarcomas. This RMAT designation represents the 38th publicly announced RMAT within the United States.

AAOM2020 37th Annual Conference & Scientific Seminar “Cutting Edge Solutions for Cutting Edge Physicians” - April 2-4 | 2020 in Washington, D.C.

The AAOM2020 conference is “Cutting Edge Solutions for Cutting Edge Physicians” and will cover the revolutionary medical breakthroughs that are transforming regenerative orthopedic medicine. The event will showcase top physicians speaking on “cutting edge topics” including case presentations, research updates, orthobiologics evaluations, functional, spine and sports medicine topics. It will also include hands-on workshops and a President’s Reception networking event. Click here to learn more.

CAR-T Cell Therapy Attracts Vast Sums of Money

Since the first CAR-T therapy approvals in 2017 by the U.S. FDA, CAR-T deal-making has attracted vast sums of money. This article summarizes recent partnerships and deal-making with the CAR-T marketplace. CAR-T therapy is a targeted approach to treating cancer that uses a patient’s T cells, which are a type of immune system cell.

What is an RMAT and Who Has One? | List of 38 RMAT Designations

The list of publicly announced RMAT’s has risen to 38. However, the U.S. FDA states it has received 115 total requests for RMAT designations and granted 44. This means that slightly over one-third of RMAT applications get approved. Adaptimmune Therapeutics' T-cell therapy ADP-A2M4 for the treatment of Synovial Sarcoma was the most recent addition on December 3, 2019.

GIOSTAR Chicago Launches GIOTalk – a New Healthcare Podcast

GIOSTAR Chicago, a leader in regenerative technologies, launched GIOTalk, a podcast focusing on stem cells and broader issues impacting the field of healthcare. Hosted by renowned plastic surgeon Dr. Michael Gellis, GIOTalk features interviews with medical practitioners and researchers, along with patients looking to share their experiences with stem cell therapy. Through these discussions, GIOSTAR Chicago seeks to provide listeners with diverse perspectives on this dynamic industry.

CBR to Acquire Natera’s Evercord™ Cord Blood Business

Cord Blood Registry (CBR), a California Cryobank Life Sciences company, is acquiring Natera’s Evercord™ cord blood business for an undisclosed sum. CBR is the largest newborn stem cell collection and storage company within the United States with more than 875,000 stem cell samples in storage. Natera is a publicly listed company (NASDAQ: NTRA) that specializes in genetic testing services.

KATAOKA Introduces CPD-017 Cell Processor for High-Speed Biomanufacturing

Kataoka-SS America, a US subsidiary of Kataoka Corporation Kyoto Japan, has launched sales of its Cell Processor CPD-017 to the U.S. market. Kataoka`s Cell Processor uses laser technology to scan, identify, and irradiate spontaneously differentiated cells without dissociation or applied stress to the cells. With the CPD-017, the process time of purifying iPSCs is significantly reduced and the adherent cell colonies can maintain a stress-free healthy condition.

What is CAR-T Cell Therapy? A New Way to Treat Cancer

CAR-T is named after a mythical creature called the chimera. A chimera is an animal made of parts of different animals attached together. With CAR-T cell therapy, a patient’s T cells are modified within a laboratory, so that they they can find and attack cancer cells. Because CAR-T cells combine different parts from different sources, they are called chimera (meaning, “blended” or “fused”) antigen receptor T cells.

Phacilitate Leaders World (Part of Advanced Therapy Week) and the World Stem Cell Summit (Jan 21-24, 2020)

Phacilitate Leaders World, now part of Advanced Therapies Week, and the World Stem Cell Summit (WSCS), will be co-hosted in Miami, FL, from January 21-24, 2020. Bringing together the entire advanced therapies ecosystem, this is the largest international conference and networking event of the year. If you're ready to join the rest of your industry peers, you can receive 10% off your delegate pass or sponsorship using the code: BIOINFORMANT.

Mesenchymal Stem Cells – Advances & Applications (30% Off)

To characterize the rapidly expanding MSC marketplace, BioInformant released a 224-page market report which explores the growing demand for MSC therapeutics, diagnostics, research tools, and manufacturing technologies. In addition to revealing trend rate data for MSC patents, grants, scientific publications, and clinical trials, it presents market size determinations with 5-year projections. Through Thursday, December 20, 2019, only, you can claim it for 30% off.